NCT00629512已完成3 期
A Comparative Efficacy and Safety Study of Nexium (Esomeprazole Magnesium) Delayed-Release Capsules (40mg qd and 20mg qd) Versus Placebo for the Prevention of Gastric Ulcers Associated With Daily NSAID Use in Patients at Risk
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 504
- 主要终点
- To assess the efficacy of esomeprazole 40 mg qd versus placebo and esomeprazole 20 mg qd versus placebo for up to 6 months of the treatment for the prevention of gastric (and/or duodenal) ulcers in patients receiving daily NSAID therapy and being at risk
研究概览
简要总结
Nonsteroidal anti-inflammatory drugs (NSAIDS) are often associated with gastric ulcers. This study looks at the prevention of these gastric ulcers with one of the three following treatment groups for up to 8 weeks: esomeprazole 40 mg once daily; esomeprazole 20 mg once daily; versus placebo; in patients at risk.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •No gastric or duodenal ulcer on baseline endoscopy.
- •A clinical diagnosis of a chronic condition that requires daily NSAID treatment for at least 6 months.
- •Other inclusion criteria, as defined in the protocol.
排除标准
- •History of esophageal, gastric or duodenal surgery, except the simple closure of an ulcer.
- •History of severe liver disease, including (but not limited to) cirrhosis and acute or chronic hepatitis.
- •Other criteria, as defined in the protocol.
研究组 & 干预措施
1
Experimental
20mg oral daily
干预措施: Esomeprazole (Drug)
2
Experimental
40mg oral daily
干预措施: Esomeprazole (Drug)
3
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
To assess the efficacy of esomeprazole 40 mg qd versus placebo and esomeprazole 20 mg qd versus placebo for up to 6 months of the treatment for the prevention of gastric (and/or duodenal) ulcers in patients receiving daily NSAID therapy and being at risk
时间窗: Assessments at Week 0, Week 4, Week 12, Week 26
次要结局
- Investigator-assessed symptoms, defined as control of NSAID-associated GI symptoms for up to 6 months of treatment with esomeprazole 40 mg qd versus placebo and esomeprazole 20mg qd versus placebo in patients receiving daily NSAID therapy.(Assessments at Week 0, Week 4, Week 12, Week 26)
- Safety and tolerability of esomeprazole 40 mg qd versus placebo and esomeprazole 20mg qd versus placebo for up to 6 months of treatment in patients receiving daily NSAID therapy(Assessments at Week 0, Week 4, Week 12, Week 26)
研究者
相似试验
已完成
3 期
A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Ranitidine 150mg Bid for the Healing of NSAID-Associated Gastric Ulcers When Daily NSAID Use is ContinuedNSAID Associated Gastric UlcersNCT00633672AstraZeneca400
已完成
3 期
A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Ranitidine 150mg Bid for the Healing of NSAID-Associated Gastric Ulcers When Daily NSAID Use is Continued in Subjects in the US OnlyNSAID Associated Gastric UlcersNCT00633412AstraZeneca400
Unknown
不适用
Non-steroidal Anti-inflammatory Drugs (NSAIDs) and Risk of Acute Kidney Injury in Patients With Heart FailureHeart FailureNCT02642081National Taiwan University Hospital100
已完成
不适用
Survey Examining the Frequency and Severity of Acid Related Symptoms While Taking NexiumGastric Acid SuppressionProton Pump InhibitorsNCT01130935AstraZeneca491
已完成
4 期
An Open-label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving NexiumGastric UlcerNCT00428701AstraZeneca40